Union Korea Pharm Co., Ltd.

A080720

KR7080720006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 22/05/2024 am IST			5-day change	1st Jan Change
6,190 ^KRW	+1.81%		-0.48%	+25.05%

25/04	Union Korea Pharm Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Mark420 Co., Ltd, NBH Capital Inc. and other investors	CI
2023	Union Korea Pharm Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Union Korea Pharm Co., Ltd. authorizes a Buyback Plan.

May 18, 2021

The Board of Directors of Union Korea Pharm Co., Ltd. has authorized a buyback plan on May 18, 2021.

Latest news about Union Korea Pharm Co., Ltd.

Union Korea Pharm Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Mark420 Co., Ltd, NBH Capital Inc. and other investors	25/04	CI
Union Korea Pharm Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Union Korea Pharm Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI
Union Korea Pharm Co., Ltd. announces an Equity Buyback for 283,333 shares.	21/22/21	CI
Union Korea Pharm Co., Ltd. authorizes a Buyback Plan.	21/22/21	CI
Union Korea Pharm Co., Ltd.'s Equity Buyback announced on October 13, 2021, has expired.	13/22/13	CI
Union Korea Pharm Co., Ltd. announces an Equity Buyback for 200,000 shares.	13/21/13	CI
Union Korea Pharm Co., Ltd. authorizes a Buyback Plan.	13/21/13	CI
Tranche Update on Union Korea Pharm Co., Ltd.'s Equity Buyback Plan announced on May 18, 2021.	11/21/11	CI
Union Korea Pharm Co., Ltd.'s Equity Buyback announced on May 18, 2021, has closed with 200,000 shares, representing 2.53% for KRW 3,104.7 million.	10/21/10	CI
Union Korea Pharm Co., Ltd. announces an Equity Buyback for 200,000 shares.	18/21/18	CI
Union Korea Pharm Co., Ltd. authorizes a Buyback Plan.	18/21/18	CI
Union Korea Pharm Co., Ltd. announced that it has received KRW 30 billion in funding from a group of investors	04/21/04	CI
Union Korea Pharm Co., Ltd. announced that it expects to receive KRW 30 billion in funding from a group of investors	30/21/30	CI
Union Korea Pharm Co., Ltd. has completed an IPO in the amount of KRW 27 billion.	23/18/23	CI
Union Korea Pharm Co., Ltd. has filed an IPO.	30/18/30	CI

Chart Union Korea Pharm Co., Ltd.

Duration

Period

More charts

UNION KOREA PHARM CO.LTD. is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Company manufactures and sells specialty medicines through formulations such as solid dosage forms, liquid injections, and cefa powder injections. Major products include antibiotics such as kepodon injection and ceftazime injection 1g for the prevention and treatment of infectious diseases; musculoskeletal drugs for treating arthritis contains unihyal injection and galithio injection; circulatory system dugs for the treatment of cerebrovascular diseases, such as cacetile tab and limasta tab; as well as drugs for digestive system such as digestive disorders. In addition, the Company engaged in the contract manufacturing operation (CMO) business for other pharmaceutical companies. The Company distributes its products within domestic market and to overseas markets including Middle East, Southeast Asia and Latin America.

Sector

Pharmaceuticals

Calendar

14/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
UNION KOREA PHARM CO., LTD.	+25.05%	3.27Cr
MERCK KGAA	+16.93%	7.94TCr
KYOWA KIRIN CO. LTD.	+9.47%	873.65Cr
SK BIOPHARMACEUTICALS CO., LTD.	-14.24%	493.63Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+49.95%	470.43Cr
YUHAN CORPORATION	+5.96%	397.8Cr
INDIVIOR PLC	+11.81%	227.56Cr
BETTA PHARMACEUTICALS CO., LTD.	-23.57%	227.72Cr
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+17.77%	213.57Cr
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-32.28%	212.07Cr